Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.43 |
| ▸ | HTR7 | P34969 | 12/20 | 0.43 |
| ▸ | HTR2A | P28223 | 9/20 | 0.43 |
| ▸ | DRD3 | P35462 | 6/20 | 0.43 |
| ▸ | HTR6 | P50406 | 6/20 | 0.43 |
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373925 | 0.90 | HTR7 (0.45) | HTR2CHTR7HTR2ADRD3HTR6 | |
| SCHEMBL2277665 | 0.88 | S1PR1 (0.42) | HTR2CHTR7HTR2ADRD3HTR6 | |
| SCHEMBL12373942 | 0.88 | GUSB (0.44) | HTR2CHTR7HTR2ADRD3HTR6 | |
| SCHEMBL12373788 | 0.88 | HTR6 (0.46) | HTR2CHTR7HTR2ADRD3HTR6 | |
| SCHEMBL12373927 | 0.88 | BRD4 (0.41) | HTR2CHTR7HTR2ADRD3HTR6 | |
| SCHEMBL12162126 | 0.87 | S1PR1 (0.48) | HTR2CHTR7HTR2ADRD3HTR6 | |
| SCHEMBL12373935 | 0.86 | GUSB (0.40) | HTR2CHTR7HTR2ADRD3HTR6 | |
| SCHEMBL12373827 | 0.81 | S1PR1 (0.42) | HTR7 | |
| SCHEMBL12373503 | 0.81 | CYSLTR1 (0.43) | HTR2CHTR7HTR2A | |
| SCHEMBL12161084 | 0.81 | HTR2C (0.52) | HTR2CHTR7HTR2ADRD3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | HTR2C 1266/4885HTR7 2085/4885HTR2A 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.